Annual report pursuant to Section 13 and 15(d)

CONVERTIBLE DEBT - Marpai Health Convertible Notes - 2020 Convertible Notes (Details)

v3.22.1
CONVERTIBLE DEBT - Marpai Health Convertible Notes - 2020 Convertible Notes (Details)
12 Months Ended
Jul. 29, 2021
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
item
Debt Instrument [Line Items]      
Cash proceeds from issuance of convertible notes   $ 550,000 $ 4,075,000
Term of debt 6 months    
2020 Convertible Notes      
Debt Instrument [Line Items]      
Number of tranches of convertible debt agreements | item     3
Aggregate principal amount     $ 4,200,000
Cash proceeds from issuance of convertible notes     1,775,000
Notes issued in exchange for legal services provided     $ 50,000
Term of debt     2 years
Minimum gross proceeds of equity financing required for automatic conversion of notes     $ 2,000,000
IPO Price As Percentage Of Per Share Public Offering Price Stated In The Final Prospectus     70.00%
Number of times the note amount, plus any accrued and unpaid interest payable upon change in control | item     1.5
Interest rate     8.00%
First tranche      
Debt Instrument [Line Items]      
Aggregate principal amount     $ 800,000
Price per share determined based on maximum pre-money valuation on a fully diluted basis     $ 8,000,000
Price per share determined based on discount on lowest price per share paid by the investors in financing round     20.00%
Second tranche      
Debt Instrument [Line Items]      
Aggregate principal amount     $ 1,500,000
Price per share determined based on maximum pre-money valuation on a fully diluted basis     $ 16,000,000
Price per share determined based on discount on lowest price per share paid by the investors in financing round     20.00%
Third tranche      
Debt Instrument [Line Items]      
Aggregate principal amount     $ 1,900,000
Cash proceeds from issuance of convertible notes     75,000
Price per share determined based on maximum pre-money valuation on a fully diluted basis     $ 35,000,000
Price per share determined based on discount on lowest price per share paid by the investors in financing round     30.00%